Cancer Drug Firm Ducks Shareholder Suit Over $26M Offering

Law360, New York (September 20, 2013, 9:04 PM ET) -- A putative class action lawsuit accusing GenVec Inc. of raising $26.2 million from shareholders to develop a pancreatic cancer treatment it knew to be ineffective was dismissed from a Maryland federal court on Friday, because the biopharmaceutical company never made material omissions.

Lead plaintiff Satish Shah launched the suit in February on behalf of investors in Gaithersburg, Md.-based GenVec, alleging the company artificially inflated its stock price through a series of misleading press releases before announcing in March 2010 that the treatment, TNFerade, had foundered during...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Shah v. Fischer et al


Case Number

8:12-cv-00341

Court

Maryland

Nature of Suit

Securities/Commodities

Judge

Deborah K. Chasanow

Date Filed

February 2, 2012

Law Firms

Companies

Government Agencies